---
document_datetime: 2023-09-21 20:05:44
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zurampic-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zurampic-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.6880103
conversion_datetime: 2025-12-15 02:26:18.662576
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zurampic

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|-----------------------------------|
| PSUSA/10470 /201912  | Periodic Safety Update EU Single assessment - lesinurad                                                                                       | 09/07/2020                                  | n/a                                         | PRAC Recommendation - maintenance |
| IB/0014              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 11/09/2019                                  | n/a                                         |                                   |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorise

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0015             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 08/08/2019   | n/a           | authorised                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------|
| PSUSA/10470 /201812 | Periodic Safety Update EU Single assessment - lesinurad                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2019   | n/a           | PRAC Recommendation - maintenance |
| PSUSA/10470 /201712 | Periodic Safety Update EU Single assessment - lesinurad                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/07/2018   | n/a           | PRAC Recommendation - maintenance |
| IB/0011/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling product | 11/06/2018   | n/a no longer | PRAC Recommendation - maintenance |
| PSUSA/10470 /201706 | down to 10-fold Periodic Safety Update EU Single assessment - lesinurad Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/01/2018   | n/a           |                                   |
| PSUSA/10470 /201612 | Periodic Safety Update EU Single assessment - lesinurad                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/07/2017   | n/a           | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0008             | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/06/2017   | 22/02/2018    | SmPC, Labelling and PL            | authorised                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------------------|-----------------------------------|
| IB/0006             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/03/2017   | n/a           |                                   |                                   |
| IAIN/0005/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.g.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supporting data product | 09/03/2017   | 22/02/2018 no | Annex II, Labelling and PL longer |                                   |
| PSUSA/10470 /201606 | Periodic Safety Update EU Single assessment - lesinurad Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/01/2017   | n/a           |                                   | PRAC Recommendation - maintenance |
| II/0002             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/09/2016   | n/a           |                                   |                                   |

<div style=\"page-break-after: always\"></div>

|         | of studies to the competent authority                                                                                                                                                                                                                                                                                                 |            |            |                     |            |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|------------|
| T/0003  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                   | 12/08/2016 | 25/08/2016 | SmPC, Labelling and |            |
| II/0001 | Submission of final study report for retrospective analysis of clinical samples to further characterize the metabolic profile of lesinurad, including metabolite M4 (Category 3 study). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 16/06/2016 | n/a        | longer              | authorised |

<!-- image -->